Incyte stock heads into the open after a 1.8% pullback
Published on 09/21/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock closed at USD 125.31 on the Nasdaq on September 18, 2026, losing 1.8% from the prior close of USD 127.62 per Nasdaq data. The share price remained within its 12 month range between USD 81.09 and USD 132.60, reflecting a pullback rather than a break of recent extremes. The session left the stock below its recent peak, with the decline roughly in line with broader pressure on growth names.
September 18, 2026 in numbers
Incyte Corp. (ISIN US45337C1027, Nasdaq: INCY) saw its shares open at USD 125.31 on September 18, 2026, compared with a prior close of USD 127.62, implying an intraday retreat of about 1.8%. Per market data, the price action unfolded within a 12 month trading span from USD 81.09 on the low side to USD 132.60 on the high side, underscoring that the latest close came closer to the top of the range than to the bottom. Trading volume on the day tracked typical levels for the stock, and the move left Incyte underperforming the Nasdaq Composite, which eased more modestly in the same session.
The session followed news that Specialised Therapeutics had expanded its partnership with Incyte to include ruxolitinib cream, marketed as Opzelura, for commercialization and registration in Australia. According to Yahoo Finance, the agreement will see Incyte retain responsibility for development and manufacturing while Specialised Therapeutics handles regulatory submissions, medical affairs, marketing and distribution across Australia. A similar release carried by StreetInsider framed the move as expanding access to Opzelura in that market. The announcement added a strategic backdrop to the share move, even as the stock ended the day lower.
Partnership and data points today
Today, September 21, 2026, investors are set to weigh the implications of the Opzelura partnership expansion as trading resumes in the United States. As The Manila Times relayed from a PRNewswire statement dated September 20, 2026, the collaboration broadens distribution of ruxolitinib cream for dermatology indications in Australia under the Opzelura brand. A brief noted by TipRanks highlighted that Incyte remains responsible for development and manufacturing while the regional partner manages commercialization. Against this backdrop, the stock enters today’s US session having recently traded below its 12 month high, with the latest close at USD 125.31 compared with the top of the range at USD 132.60, a gap of USD 7.29 that may influence how investors position around upcoming dermatology and oncology news flows.
